bank of america merrill lynch health care conference · company’s most recent annual report on...
TRANSCRIPT
![Page 1: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/1.jpg)
NOT FOR PRODUCT PROMOTIONAL USE
Bank of AmericaMerrill Lynch
Health Care ConferenceGiovanni Caforio, M.D.
President, U.S. Pharmaceuticals
1
May 15, 2013
![Page 2: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/2.jpg)
NOT FOR PRODUCT PROMOTIONAL USE
Forward-Looking Information and Non-GAAP Financial Information
During this meeting, we will make statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports onForm 10-Q and Form 8-K. These documents are available from the SEC, theBristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.
In addition, any forward-looking statements represent our estimates only asof today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
During this meeting, we will also discuss certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.
2
![Page 3: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/3.jpg)
NOT FOR PRODUCT PROMOTIONAL USE
Agile, Entrepreneurial & Accountable Culture
Benchmark BioPharma Company
Our Strategic Foundation
Innovation SelectiveIntegration
ContinuousImprovement
3
Helping more patients prevail in their fight against serious disease
Best of PharmaBest of Biotech
![Page 4: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/4.jpg)
NOT FOR PRODUCT PROMOTIONAL USE
A Diversified Product Portfolio
Key Brands
4
Q1 US revenue growth (ex. Plavix & Avapro) of 9%
![Page 5: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/5.jpg)
NOT FOR PRODUCT PROMOTIONAL USE
Unique and differentiated profile
U.S. launch with Pfizer is under way
Near term life-cycle opportunities
5
Building a foundation for future leadership
![Page 6: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/6.jpg)
NOT FOR PRODUCT PROMOTIONAL USE
Broad portfolio to address patient needs
U.S. alliance focused to deliver on long-term growth
Upcoming catalysts:
– SAVOR results mid-year
– Planned re-filing of Forxiga this summer
6
Diabetes: Establishing Leadership Position
![Page 7: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/7.jpg)
NOT FOR PRODUCT PROMOTIONAL USE 7
Strong launch and continued growth
Leveraging potential for long-term survival
Leadership in immuno-oncology
– Nivolumab (anti-PD-1)
– Earlier stage assets
![Page 8: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/8.jpg)
NOT FOR PRODUCT PROMOTIONAL USE
Confident in Our Future
Strong Growth
New Product Opportunities
Late-Stage Pipeline
8
Positioned for Long-Term Success
![Page 9: Bank of America Merrill Lynch Health Care Conference · company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from](https://reader035.vdocuments.us/reader035/viewer/2022070822/5f24fd74eeaee3174d2fd7ae/html5/thumbnails/9.jpg)
NOT FOR PRODUCT PROMOTIONAL USE
Bank of AmericaMerrill Lynch
Health Care ConferenceGiovanni Caforio, M.D.
President, U.S. Pharmaceuticals
9
May 15, 2013